Active substanceBicalutamideBicalutamide
Similar drugsTo uncover
  • Androblock®
    pills inwards 
  • Balutar®
    pills inwards 
    TAD Pharma GmbH     Germany
  • Bicalutamide
    pills inwards 
    BIOCAD, CJSC     Russia
  • Bicalutamide
    pills inwards 
    ATOLL, LLC     Russia
  • Bicalutamide
    pills inwards 
    BIOCAD, CJSC     Russia
  • Bicalutamide
    pills inwards 
  • Bicalutamide
    pills inwards 
  • Bicalutamide
    pills inwards 
  • Bicalutamide Grindeks
    pills inwards 
    GRINDEX, JSC     Latvia
  • Bicalutamide Cabi
    pills inwards 
  • Bicalutamide Canon
    pills inwards 
  • Bicalutamide Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Bicalutamide-Siguardis
    pills inwards 
    SIGARDIS ENG, LLC     Russia
  • Bicalutamide-Teva
    pills inwards 
  • Bicutulter
    pills inwards 
  • Bicutulter
    pills inwards 
  • Bicane®
    pills inwards 
    NATIVA, LLC     Russia
  • Bikaprost®
    pills inwards 
  • Bilumide®
    pills inwards 
    VEROPHARM SA     Russia
  • Bilumide®
    pills inwards 
    VEROPHARM SA     Russia
  • Calumid®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Calumid®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Casodex®
    pills inwards 
    AstraZeneca UK Ltd     United Kingdom
  • Casodex®
    pills inwards 
    AstraZeneca UK Ltd     United Kingdom
  • Dosage form: & nbspfilm-coated tablets
    Composition:

    For one tablet:

    Active substance:

    Bicalutamide

    50.0 mg

    150.0 mg

    Excipients:

    Lactose monohydrate (milk sugar)

    61.0 mg

    183.0 mg

    Potato starch

    27.0 mg

    81.0 mg

    Povidone K 25 (polyvinylpyrrolidone K25)

    7.0 mg

    21.0 mg

    Sodium carboxymethyl starch

    3.0 mg

    9.0 mg

    Magnesium stearate

    1.0 mg

    3.0 mg

    Silica colloidal dioxide

    1.0 mg

    3.0 mg

    Weight of the core tablet

    150.0 mg

    450.0 mg

    Shell composition:

    Aquarius Prime VAR218010 White [hypromellose - 65%,

    titanium dioxide-25%, macrogol (polyethylene glycol) - 10%]

    4.5 mg

    13.5 mg

    Film coated tablet weight

    154.5 mg

    463.5 mg

    Description:

    Round, biconvex tablets, covered with a film coat of white color.

    Pharmacotherapeutic group:Antitumor agent - antiandrogen
    ATX: & nbsp

    L.02.B.B.03   Bicalutamide

    Pharmacodynamics:

    Bicalutamide is a racemic mixture with non-steroidal antiandrogenic activity predominantly (R) -enantiomer, does not have a different endocrine activity. Bicalutamide binds to androgen receptors and, without activating the expression of genes, suppresses the stimulating effect of androgens. The result is regression of malignant neoplasms of the prostate gland.

    In some patients, discontinuing bicalutamide may lead to the development of a clinical "anti-androgen withdrawal syndrome".

    Pharmacokinetics:

    After oral administration, it is quickly and completely absorbed from the gastrointestinal tract. Eating does not affect absorption.

    (S) -enantiomer is eliminated much faster from the body (R) -enantiomer, the half-life of the latter is about 7 days.

    With daily intake of bicalutamide, the concentration (R) -enantiomer in plasma increases approximately 10-fold due to a long half-life, which makes it possible to take the drug once a day.

    With a daily intake of bicalutamide in a dose of 50 mg, the equilibrium concentration (R) - the enantiomer in plasma is about 9 μg / ml.When 150 mg of bicalutamide is taken daily, the equilibrium concentration (R) -enantiomer is about 22 μg / ml. At an equilibrium state, about 99% of all enantiomers circulating in the blood is active (R) -enantiomer.

    On the pharmacokinetics (R) -enantiomer do not affect age, impaired renal function, mild and moderate impairment of liver function. There is evidence that in patients with severe impairment of liver function, elimination is slowed (R) -enantiomer from the plasma.

    The association with plasma proteins is high (for a racemic mixture of 96%, for (R) -enapthiomer 99.6%). Intensively metabolized in the liver (by oxidation and the formation of conjugates with glucuronic acid). Metabolites are excreted in urine and bile approximately in equal proportions.

    Indications:

    - Common prostate cancer in combination with an analogue of GnRH (gonadotropin-releasing hormone) or surgical castration;

    - locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0) as monotherapy or adjuvant therapy in combination with radical prostatectomy or radiotherapy;

    - locally advanced nonmetastatic prostate cancer in cases where surgical castration or other medical interventions are not applicable or are unacceptable.

    Contraindications:

    - Hypersensitivity to bicalutamide and auxiliary components of the drug;

    - simultaneous reception with terfenadine, astemizole and cisapride;

    - bicalutamide should not be given to children and women.

    Due to the presence of lactose in the composition: lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

    Carefully:Violation of the function of the liver.
    Pregnancy and lactation:Bicalutamide is contraindicated in women and should not be given to pregnant and lactating mothers.
    Dosing and Administration:

    Adults and older men:

    With advanced prostate cancer in combination with an analogue of GnRH or surgical castration: inside by 50 mg once a day. Treatment Bicalutamide it is necessary to start simultaneously with the start of the GnRH analogue or surgical castration.

    With locally advanced prostate cancer: inside by 150 mg one once a day. Bicalutamide should be taken for a long time, at least for 2 years. If signs of disease progression appear, the drug should be discontinued.

    Renal impairment: correction of the dose is not required.

    Dysfunction of the liver: correction of the dose is not required for mild and moderate hepatic insufficiency. In severe hepatic insufficiency, despite the fact that T1/2 of the active enantiomer of bicalutamide is increased by 76%, however, no dose adjustment is required.

    Side effects:

    The pharmacological action of bicalutamide can cause the following side effects:

    - very often (> 10%): gynecomastia (can persist even after cessation of therapy, especially in case of taking the drug for a long time), tenderness of the mammary glands, hot flashes;

    - often (≥1% and <10%): diarrhea, nausea, transient increase in the activity of "liver" transaminases, cholestasis and jaundice (described changes in liver function were rarely evaluated as serious, transient, completely disappeared, or decreased with continued therapy or after drug withdrawal), itching, asthenia: when applied drug in a daily dose of 150 mg - alopecia or hair regrowth, decreased sexual desire, sexual dysfunction, weight gain.

    - rarely (≥0,1% - <1%): hypersensitivity reactions, including angioedema and hives, interstitial lung diseases; when using the drug in a daily dose of 150 mg - abdominal pain, depression, dyspepsia, hematuria;

    - rarely (≥0,01% - <0,1%): vomiting, dry skin (with the use of the drug in a daily dose of 150 mg, dry skin is often observed), liver failure (the cause-and-effect relationship with bicalutamide is not established reliably).

    With the simultaneous use of bicalutamide and GnRH analogues, the following adverse events with a frequency of ≥ 1% can also be observed (the cause-and-effect relationship with the drug administration has not been established, some of the noted side effects have been observed in elderly patients):

    From the cardiovascular system: heart failure.

    From the gastrointestinal tract: anorexia, dry mouth, indigestion, constipation, flatulence.

    From the central nervous system: dizziness, headache, insomnia, increased drowsiness.

    From the respiratory system: dyspnea.

    From the genitourinary system: sexual dysfunction, nocturia, polyuria.

    From the hematopoietic system: anemia.

    From the skin and its appendages: alopecia, skin rash, excessive sweating, hirsutism.

    Other: diabetes, hyperglycemia, increased or decreased body weight, abdominal pain, chest pain, pelvic pain, chills.

    Overdose:

    Cases of overdose in humans are not described. There is no specific antidote.

    Treatment symptomatic. Dialysis is not effective, because bicalutamide strongly binds to plasma proteins and is not excreted in the urine unchanged. It shows general supportive therapy and monitoring of vital body functions.

    Interaction:

    There is no evidence of pharmacokinetic or pharmacodynamic interactions between bicalutamide and GnRH analogues.

    In studies in vitro shown, that (R) -enantiomer of bicalutamide inhibits isoenzyme CYP3A4, to a lesser extent affecting the activity of isoenzymes CYP2C9, 2C19 and 2D6. The potential ability of bicalutamide to interact with other drugs has not been detected, but when used for 28 days against the background of the administration of midazolam, the area under the concentration-time curve (AUC) midazolam increases by 80%.

    Incompatible with terfenadine, astemizole, cisapride.

    Caution should be exercised in prescribing bicalutamide simultaneously with cyclosporine or blockers of "slow" calcium channels. It may be necessary to reduce the dose of these drugs, especially in the case of potentiation or the development of side effects.After the beginning of the use or elimination of bicalutamide, it is recommended that the concentration of cyclosporin in the plasma be carefully monitored and the patient's clinical condition monitored.

    Simultaneous application of bicalutamide formulations and inhibitors of microsomal oxidation of drugs, such as ketoconazole or cimetidine may lead to an increase in plasma concentrations of bicalutamide, and possibly an increase in the incidence of adverse effects.

    Strengthens the effect of indirect anticoagulants (coumarin derivatives), incl. warfarin (competition for communication with plasma proteins).

    Special instructions:

    Given the possibility of slowing the excretion of bicalutamide and its cumulation in patients with impaired liver function, it is advisable to periodically evaluate liver function. Most liver function changes occur during the first six months of treatment bicalutamide.

    In case of pronounced changes in liver function, bicalutamide should be discontinued.

    In patients with progression of the disease against a background of increasing concentrations of prostate-specific antigen (PSA), consideration should be given to discontinuing treatment bicalutamide.

    In the appointment of bicalutamide to patients receiving indirect anticoagulants (coumarin derivatives), incl. warfarin, it is recommended to monitor prothrombin time on a regular basis.

    Each tablet of the drug Bicalutamide 50 mg contains 61 mg of lactose monohydrate. Each tablet of the drug Bicalutamide 150 mg contains 183 mg of lactose monohydrate.

    Taking into account the possibility of bicalutamide inhibition of the activity of cytochrome P450 (isoenzyme CYP3A4), caution should be exercised in the simultaneous administration of bicalutamide with drugs predominantly metabolized with the participation of the isoenzyme CYP3A4.

    Effect on the ability to drive transp. cf. and fur:

    Bicalutamide can affect the ability of patients to drive vehicles or engage in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions due to the development of dizziness and drowsiness in the combined use of bicalutamide and GnRH analogues.

    Form release / dosage:

    Film-coated tablets, 50 mg and 150 mg.

    Packaging:

    By 7 or 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foilprinted lacquered.

    By 21, 28, 30 or 40 tablets in a can of polymer for medicines. Free space in the bank is filled with cotton hygroscopic cotton.

    Each bank, 4 or 3 contour cellular packs (7 or 10 tablets respectively) together with the instruction for use is placed in a pack of cardboard.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    The drug should not be used after the expiry date indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-003622/10
    Date of registration:23.08.2010 / 04.06.2013
    The owner of the registration certificate:TECHNOLOGY OF DRUGS, LTD. TECHNOLOGY OF DRUGS, LTD. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp25.01.2017
    Illustrated instructions
      Instructions
      Up